Clinical Trial Update: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). [Phase 4]

View source ↗

Summary

Phase IV randomized study comparing palbociclib plus endocrine therapy to a chemotherapy-based strategy in HR-positive/HER2-negative metastatic breast cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Metastatic Breast Cancer | Phase 4 | Status: COMPLETED